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Abstract: The selective transportation of therapeutic agents to 
tumoral cells is usually achieved by their conjugation with targeting 
moieties able to recognize these cells. Unfortunately, simple and 
static targeting systems usually show selectivity lacks. Herein, 
double sequential encrypted targeting system is proposed as stimuli-
responsive targeting analogue for selectivity enhancement. The 
system is able to recognize diseased bone tissue in first place, and 
once there, a hidden secondary targeting group is activated by the 
presence of an enzyme overproduced in the malignant tissue 
(cathepsin K), triggering the recognition of diseased cells. 
Transporting the cell targeting agent in a hidden conformation which 
contains a high selective tissular primary targeting, could avoid not 
only its binding to similar cell receptors but also the apparition of the 
binding-site barrier effect, which can enhance the penetration of the 
therapeutic agent within the affected zone. This strategy could be 
applied not only to conjugate drugs but also to drug loaded 
nanocarriers in order to improve the efficiency for bone cancer 
treatments. 
The selectivity lack of cytotoxic drugs results in an ineffective 
delivery of them in tumoral tissues, which strongly reduces their 
efficacy and causes the apparition of systemic toxicity in usual 
cancer treatments.[1] Moreover, even if the drug reaches the 
tumoral area, it should be face a complex scenario. A solid 
tumor is an extraordinary heterogeneous tissue formed by 
myriad of different malignant, harmless, even supportive cells, 
which play different roles in tumor progression.[2] Therefore, it is 
necessary to design smart therapeutic agents with the ability to 
distinguish between healthy and tumoral cells in order to 
enhance their efficiency through the concentration of their 
cytotoxic capacity exclusively in malignant cells. One of the 
promising alternatives for improving the selectivity of 
chemotherapy is the covalent conjugation of vectorization 
moieties or targeting systems, directly on the surface of  drug-
loaded nanocarriers,[3] with both  inorganic[4],[5] and organic 
nature,[6],[7] as well as, with the own free drugs[8] generating 
vectorized drug conjugates. There are a wide variety of targeting 
systems, from big biomolecules as antibodies,[9] lipoproteins[10] 
or oligonucleotide sequences[11] to small molecules such as 
vitamins,[12] sugars[13] or synthetic molecules.[14] These moieties 
are characterized by their capacity to recognize and specifically 
bind to membrane cell receptors which are only, or mainly 
expressed by tumoral cells. Unfortunately, the use of targeting 
moieties is not free of drawbacks presenting some unwanted 
effects as off-target by protein corona[15] or non-desired 
modifications in the ligand during the conjugation process,[16] 
besides the cross interactions between the targeting group and 
cell receptors expressed in healthy cells. On the other hand, 
strong binding affinity between the vectorization motif and its cell 
receptor severely hampers the penetration of the therapeutic 
agent within the tumor. The apparition of this well-known effect, 
called binding-site barrier, is common in both, drug conjugates[17] 
and targeted nanoparticles[18] and compromises the efficacy of 
the therapy by accumulation of  targeted systems mainly in the 
tumor periphery inducing outside weak local effects. 
Hierarchical targeting has been recently proposed as a novel 
strategy able to overcome these limitations in the case of 
nanometric carriers.[19] However,  using shielded targeting 
agents in this context  makes EPR[20],[21]  effect as solely 
responsible for nanocarrier accumulation in tumoral tissues.[22] 
Therefore, the achieved gain regarding lower cross interactions 
and higher penetration could be counteracted by the lower 
amount of nanocarriers which reach the diseased zone. 
Additionally, this approach is hardly adaptable to the direct 
conjugation with small drugs, due to these therapeutic agents do 
not present EPR effect, as a consequence of their smaller size. 
   
Herein, we propose a novel approach equally applicable both 
drug conjugates and nanocarriers. This concept is based on a 
double sequential encrypted targeting system (DSETS) capable 
to combine tissular and cellular targeting following an activatable 
cascade mechanism. As proof of concept, we have focused on 
bone tumors. Thereby, we have chosen an uncovered primary 
tissue targeting agent, bisphosphonate (BP) specific for exposed 
diseased bone tissue, and secondary hidden cellular targeting 
“RGD type”. The peptide has been encrypted inside an 
oligopeptide sequence RPGRDGRC (Arg-Pr-Gly-Arg-Asp-Gly-
Arg-Cys) and has been sterically covered with a 
polyethylenglycol 3500 Da, (PEG) moiety, making it more inert in 
presence of its receptors. Then, the RGD pattern becomes 
exposed only in the presence of elevated concentrations of 
cathepsin-K (CK), characteristic behavior of bone tissues with 
high osteoclast activity such as many primary and metastatic 
bone tumors [23],[24]  (Scheme 1.) This novel targeting moiety is 
based on the combination of two widely employed targeting 
agents as are both; alendronate[25] (ALN) and RGD 
tripeptide.[26],[27] Alendronate shows high avidity by 
hydroxyapatite and therefore, this molecule strongly binds to the 
mineral part of bone tissues.[28]  
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Scheme 1. Mode of action of the double sequential targeting system in osteosarcoma diseased bone. I) Bone fixing HA-BP, II) Cathepsin-K induced peptide 
proteolysis and III) RGD peptide recognition by HOS cells wall and subsequent internalization.
On the other hand, RGD pattern is a well-known sequence 
which binds to α,β-integrin and Neuropilin (NRP)-1 receptors 
which are usually overexpressed in many tumoral cell lines and 
also in tumoral blood vessels.[29] 
However, integrin receptors are also present in many healthy 
cells and therefore, the direct conjugation of RGD sequences on 
the transported specie could misdirect the therapeutic cargo to 
unwanted locations. The combination of both vectorization 
capacities (tissular and cellular targeting) converts this modular 
targeting system into a promising prototype for delivering 
therapeutic agents to bone tumors. For affording the targeting 
device, the first step was the synthesis of the polypeptide strand 
which was made using solid phase chemistry starting by Fmoc-
Arg(Pbf)-Wang resin (see supporting information for the detailed 
protocol). 
 
Scheme 2. Synthetic pathway for affording fluorescent dual-targeting moiety.   
Following the typical Fmoc-deprotection and HBTU/HOBT-
mediated carboxylic acid activation steps, each aminoacids was 
introduced in the peptide strand (Scheme 2a). The tripeptide 
Arg-Pr-Gly motif was introduced in the sequence for providing 
selective responsivity to CK. This enzyme performs the 
proteolysis of collagen I catalyzing almost exclusively the rupture 
of the amide bond present in the helix after Pr-Gly motif.[30],[31]  
 
In order to evaluate the sensitivity and selectivity against CK, a 
small amount of the peptide strand (10 mg) was exposed to an 
acidic solution of this enzyme (pH = 5) during two hours at 37 ºC, 
replicating osteoclast lacuna conditions. Whereas, other batch 
was only exposed to mild acidic medium. After isolation process, 
the resulted crudes were analyzed by matrix-assisted laser 
desorption/ionization (MALDI) time-of-flight/time-of-flight 
(TOF/TOF). As it was expected, when the peptide was exposed 
to CK, Arg-Asp-Gly-Arg-Cys was the mayor product, as 
corresponds to the amide bond rupture after glycine in Pr-Gly 
(Figure S10). This result confirm that CK induces the responsive 
behavior of the peptide strand in front of the stability showed in 
enzyme-free conditions. A fluorescent labeled polyethylenglycol 
(F-PEG) was employed as therapeutic cargo model. This 
polymeric strand mimics the role of nanometric drug-loaded 
carrier or therapeutic macromolecule allowing an easy 
visualization and quantification of the system internalization 
within malignant cells, as it has been reported elsewhere.[32] F-
PEG-Maleimide was attached to the cysteine end through thiol-
ene reaction. Alendronate was conjugated via carbodiimide 
chemistry to the carboxylic acid end of a bifunctional HO2C-
PEG-NH2 chain of 3500 Da of molecular weight in order to shield 
more properly the cellular targeting moiety. Finally, this system 
was attached on the fluorescent peptide strand using again a 
carbodiimide, as carboxylic acid activator. (Scheme 2b).   
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Once the system was prepared, its performance was evaluated 
step by step. Firstly, its capacity to bind apatite was tested by 
incubating the complete system in the presence of pure 
hydroxyapatite discs (HA) in PBS, pH=7.4 at 37ºC, during 8 
hours simulating body fluids conditions. The peptide sequence 
without PEG-alendronate moiety was employed as control. After 
this time, the discs were thoroughly washed with buffer in order 
to eliminate the physically adsorbed systems and their presence 
was determined by fluorescence microscopy. As it was expected, 
the peptides without alendronate were not able to bind to the 
surface of HA discs whereas the peptides with alendronate were 
strongly retained on HA surface (Figure 1a). Further, binding 
capacity was also evaluated in the presence of Ca2+ at 
concentration of 2.5 mM, which is naturally present in bone 
tissue surrounding. HA discs with complete system was 
incubated in the presence of physiological concentration of Ca2+ 
showing the retention of fluorescence in a similar amount than 
controls without Ca2+ (Figure 1b). As it is shown in the figure 1b, 
it was necessary to double this concentration for releasing in a 
significant amount the targeting moiety. 
 
In order to prove that the binding capacity of the complete 
system was due to the complexation of alendronate on HA 
surface, competition experiments with free alendronate were 
carried out. As is shown in Figure 1c, the system ability to be 
retained on HA surface decreased when alendronate 
concentration was higher, due to free alendronate was gradually 
replacing the complete targeting device from the surface. In all 
experiments, the targeting system release was confirmed by 
fluorescence measurements of the solutions before and after the 
alendronate exposition (Graphic S1). In sight of these evidences, 
the active primary targeting inside the complete system showed 
a good performance in close reality conditions for vectorization 
to diseased bone. 
Figure 1. a) Fluorescence microscopy HA discs exposed to the targeting 
device with and without PEG-alendronate. Fluorescence microscopy of HA 
discs exposed to complete targeting device in the presence of different 
concentrations of   b) Ca2+ and c) free alendronate. 
The next step was to evaluate the performance of the hidden 
secondary targeting sequence. For this aim, Human 
Osteosarcoma cells (HOS) was chosen as tumoral cell model 
because they usually overexpress α,β-integrin[33] and (NRP)-1 
receptors[34] which interact with the RGD pattern. Further, 
osteosarcoma is one of the most common non-hematologic 
neoplasm which affects to bone tissues.[35] The capacity to hide 
the secondary targeting was evaluated exposing HOS cells to a 
fixed concentration of complete system (10 µg/mL) during 2 
hours. The same protocol was carried out employing a 
fluorescent PEG strand (F-PEG) as negative control and a 
fluorescent PEG strand decorated with CRGDR as positive 
control (F-PEG-CRGDR), respectively. The percentage of cells 
that internalize the fluorescent strands in each case was 
measured using flow cytometry.  Almost 20% of HOS cells 
internalize the fragment which contains the unshielded RGD 
pattern in comparison with only 8% of cells which engulf the 
fluorescent PEG, which confirm that the RGD sequence 
enhances the internalization within malignant cells (Figure 2). 
Interestingly, targeting uptake was only 12% (all data normalized 
with control) when the complete system that contains the shield 
pattern was employed, which correspond to around 40% of 
decrease in targeting internalization. Thus, these results point 
out a good performance of both encryption and cell targeting 
capacity of the hybrid strand.  
Figure 2. Studies of internalization capacity of F-PEG, F-PEG-CRGDR and F-
PEG-CRGDR-Encryp-ALN in HOS. Error data and statistical analysis in 
supporting information. 
Finally, the complete system was tested employing a 
“bone/culture in vitro model”. In this model, HA discs were 
previously incubated with PBS solution which contains 300 
µg·mL-1 of complete system. After 8 hours, the discs were 
thoroughly washed with buffer in order to remove the 
physisorbed peptide. Once the discs were washed, they were 
placed on upper sheet of transwells and the cells were cultured 
in the inserts. Then, a solution of CK in mild-acidic media was 
added to three wells while other three batches were only 
exposed to the mild-acidic solution without the enzyme and they 
were incubated during 2 hours. After the incubation time, HA 
discs were retired and cell cultures were washed with PBS and 
incubated with medium during 24 hours more.  
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The targeting internalization in each well were analyzed by flow 
cytometry showing that, in the samples where cathepsin-K was 
added, around 90 % of cells showed fluorescence which 
indicates the internalization of the labeled peptide. On contrary, 
in the wells incubated without CK, only around 10 % of the cells 
exhibited fluorescence. The presence of the peptide in each disc 
was observed by fluorescence microscopy showing that discs 
which were treated with incubated proteolytic enzyme lost all the 
fluorescence whereas in whose without the enzyme, the 
fluorescence is almost completely retained (Figure 3). 
Figure 3.  Cathepsin-K responsive behavior in HOS before and after CK by a) 
fluorescence microscopy of HA discs addition,  b) percentage of cells which 
have engulfed the fluorescent label. * P<0.01 
Osteosarcoma has been chosen as proof of concept of a 
common solid tumor and therefore, the primary and secondary 
targeting groups were selected accordingly. But it is worth noting 
that this strategy could be easily adapted to different tumors 
which affect to different organs or tissues. In conclusion, 
encrypted   targeting agents would avoid the misdirection of the 
transported species to other tissues reducing the apparition of 
side effects or systemic toxicity. Additionally, the primary 
targeting group located at the end of full system provides the 
guiding capacity to the affected tissue.  This novel targeting 
system represents a new approach for the selectivity 
enhancement in drug delivery processes and it could be applied 
for several types of drug conjugates, drug loaded nanocarriers 
or imaging agents, increasing the available arsenal in the fight 
against tumors. 
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